Platinum-resistant Recurrent Ovarian Cancer
Platinum-resistant recurrent ovarian cancer is a type of ovarian cancer that does not respond to platinum-based chemotherapy treatments and tends to recur after initial treatment.
Solid Tumors: AZD5335 Treatment Study
We are investigating the safety and effectiveness of AZD5335, both alone and with other treatments, for people with solid tumors. This study will help us understand how the drug works in the body.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Platinum-sensitive Recurrent Ovarian Cancer
Platinum-sensitive recurrent ovarian cancer is a type of ovarian cancer that responds to platinum-based chemotherapy and can recur after initial treatment.
Lung Adenocarcinoma
Lung adenocarcinoma is a common type of non-small cell lung cancer that originates in the glandular cells of the lungs and can cause symptoms like persistent cough and chest pain.
Endometrial Cancer
Endometrial cancer is a type of cancer that begins in the lining of the uterus and is often associated with symptoms like abnormal bleeding and pelvic pain.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Charite Universitaetsmedizin Berlin KöR
Klinik fuer Gynaekologie mit Zentrum fuer onkologische Chirurgie
Berlin, Germany
KEM I Evang. Kliniken Essen-Mitte gGmbH
Gynaekologie & Gynaekologische Onkologie
Essen, Germany
Medical Center - University Of Freiburg
Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation
Freiburg, Germany
Sponsor: AstraZeneca AB
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.